Maybe you didn't even know there was a biotech dip. If all you've been following in the sector is a stock like Nektar Therapeutics (NKTR), a Jubak Picks member (and the call options are a holding in my Volatility Portfolio), you're likely to respond "What dip?" Nektar is up, 325% for 2017 to date and […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
